Skip to content
Back to meeting Original
UroToday.com· @urotoday · X·· 5 hours agoScore45

ivonescimab

Body

Efficacy and Safety of Ivonescimab as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma. Presented by Dr. Jun Guo, #ESMO26 written coverage by @rksayyid > https://bit.ly/4yCDLDt #KidneyCancer #RCC #Immunotherapy @myESMO

68 views · 0 likes · 0 reposts · 0 replies

Source: UroToday.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.